Nuvation Bio (NUVB) is addressing unmet medical need in cancer with lead approved drug Ibtrozi, and clinical testing Safusidenib for high grade glioma. The company released second quarter financial results before market open today. The company is gaining traction with new patients for lead drug Ibtrozi. The drug has been FDA approved for ROS1 NSCLC since June of 2025. Some key highlights from the second quarter results below.
- $31.7 million in second quarter total revenue
- $23.2 Ibtrozi US revenue
- 30% quarter over quarter TKI naive growth
- License and collaboration revenue of $8.5 million
- Cash equivalents of $696 million
- Current Market cap of $2.3B
The net loss was $62.8 million for the quarter, or (.18) per share.
Second drug Safusidenib is currently in phase 3 testing with the SIGMA trial for high grade glioma, with expected completion around 2029. The trial can be viewed here NCT05303519.
All prior Nuvation posts can be viewed here Nuvation Bio Posts. Thank you for reading.
Disclaimer: This stock, or any other stock referenced on this site, is for educational purposes only, not personalized advice. Consult with your investment advisor professional, prior to buying stocks, precious metals, commodity's, or crypto.
